Table 1 : Clinical characteristics of the patients in the subgroups.


  AIA+ATA(n=17) AIA(n=7) ATA(n=10) p-value
AIA vs. ATA

Age (yr.) 45.9±11.7 45.3±11.9 46.3±12.21 0.87
45 (35-56) 46 (34-57) 44(39-56)
Female / Male, no. 10/7 2/5 8/2 0.051
Duration of astma (yr.) 7.82±6.89 8.7±5.15 7.2±8.11 0.28
6(3-10) 6(5-14) 3.5(1-10)
Inhaled steroids (yes/no), no. 11/6 1/6 5/5 0.31
Inhaled steroids (g of fluticasone equivalent/d) 426.5±490.3 678.6±590.1 250±333.33 0.08
250(0-500) 500(250-1500) 125(0-500)
FEV1 baseline (% predicted) 89.64±10.58 86.79±10.06 91.64±11 0.37
89.56(82.77-94.44) 85.26(80.53-93.24) 94.25(82.77-97.2)
Total IgE (IU/mL) 100.9±149.4 69.44±30.35 122.86±194.35 0.46
52.4(23-92) 76(46.1-92) 40.5(20-94)
Skin prick test (positive/negative), no. 11/6 4/3 7/3 0.97
Blood eosinophil count (mm-3) 315.9±224.9 477.57±261.08 202.8±99.58 0.03*
284(200-339) 484(284-792) 223.5(121-285)
NHLBI asthma grade 1.29±0.47 1.4±0.53 1.2±0.42 0.35
1(1-2) 1(1-2) 1(1-1)
ACT 22.71±3.35 20.7±4.46 24.1±1.2 0.13
24(22-25) 22(16-25) 24.5(24-25)
PD20 (mg of histamine) 926.5±709.2 414.29±320.38 1285±692.07 0.008*
960(350-1100) 350(155-505) 1100(960-1850)

* statistical significance values are expressed as mean±SD and median with upper and lower quartile (25% and 75% percentiles).
ACT: Asthma Control Test; AIA: aspirin-induced asthma, ATA: aspirin-tolerant asthma, FEV1: forced expiratory volume in 1 second,
IgE: immunoglobulin E, IU: international unit, N.S: not significant, NHLBI: The National Heart, Lung, and Blood Institute; no., number;
PD20: provocative dose; y, year.

Kaszuba et al.Hypersensitivity  2013 1:4DOI : 10.7243/2052-594X-1-4